Endo International PLC (NASDAQ:ENDP) was upgraded by stock analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday. The firm currently has a $19.14 target price on the stock. Vetr‘s target price would indicate a potential downside of 4.47% from the stock’s current price.
Other research analysts have also recently issued reports about the company. Deutsche Bank AG reaffirmed a “buy” rating and issued a $61.00 target price (down from $65.00) on shares of Endo International PLC in a research report on Monday, April 18th. Citigroup Inc. cut their price objective on Endo International PLC from $72.00 to $40.00 and set a “buy” rating for the company in a report on Friday, April 29th. Stifel Nicolaus cut their price objective on Endo International PLC from $90.00 to $75.00 and set a “buy” rating for the company in a report on Friday, May 6th. Guggenheim reissued a “buy” rating and set a $35.00 price objective (down from $65.00) on shares of Endo International PLC in a report on Saturday, May 7th. Finally, JMP Securities reissued a “buy” rating and set a $52.00 price objective (down from $56.00) on shares of Endo International PLC in a report on Sunday, May 8th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $40.00.
Endo International PLC (NASDAQ:ENDP) traded down 2.978% during trading on Monday, hitting $20.035. 3,557,923 shares of the stock traded hands. Endo International PLC has a one year low of $12.56 and a one year high of $84.57. The stock’s market cap is $4.46 billion. The company has a 50-day moving average price of $20.38 and a 200 day moving average price of $23.69.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/11/endo-international-plc-endp-upgraded-to-strong-buy-by-vetr-inc.html
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.12. The business had revenue of $921 million for the quarter, compared to the consensus estimate of $873.50 million. Endo International PLC had a negative net margin of 25.90% and a positive return on equity of 15.54%. Endo International PLC’s quarterly revenue was up 25.3% on a year-over-year basis. During the same quarter last year, the company posted $1.08 earnings per share. Analysts expect that Endo International PLC will post $4.56 earnings per share for the current year.
Several large investors recently added to or reduced their stakes in the stock. Rhenman & Partners Asset Management AB raised its position in Endo International PLC by 124.1% in the first quarter. Rhenman & Partners Asset Management AB now owns 260,000 shares of the company’s stock worth $7,319,000 after buying an additional 144,000 shares during the last quarter. Exxonmobil Investment Management Inc. TX raised its position in Endo International PLC by 6.7% in the first quarter. Exxonmobil Investment Management Inc. TX now owns 49,773 shares of the company’s stock worth $1,401,000 after buying an additional 3,115 shares during the last quarter. Norges Bank acquired a new position in Endo International PLC during the fourth quarter worth approximately $97,137,000. United Services Automobile Association raised its position in Endo International PLC by 62.5% in the fourth quarter. United Services Automobile Association now owns 100,499 shares of the company’s stock worth $6,153,000 after buying an additional 38,652 shares during the last quarter. Finally, Bellevue Asset Management AG raised its position in Endo International PLC by 8.2% in the fourth quarter. Bellevue Asset Management AG now owns 171,000 shares of the company’s stock worth $10,469,000 after buying an additional 13,000 shares during the last quarter. 96.83% of the stock is owned by institutional investors.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Endo International PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Endo International PLC and related companies with MarketBeat.com’s FREE daily email newsletter.